You can seek FDA approval to launch a generic drug before the expiration of ANDROGEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ANDROGEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ANDROGEL:-

You can seek FDA approval to launch a generic drug before the expiration of ARICEPT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ARICEPT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ARICEPT:-

You can seek FDA approval to launch a generic drug before the expiration of COMBIVENT RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMBIVENT RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMBIVENT RESPIMAT:-

You can seek FDA approval to launch a generic drug before the expiration of GENVOYA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GENVOYA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GENVOYA:-

You can seek FDA approval to launch a generic drug before the expiration of JUVISYNC's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JUVISYNC's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JUVISYNC:-

You can seek FDA approval to launch a generic drug before the expiration of MAKENA (AUTOINJECTOR)'s patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MAKENA (AUTOINJECTOR)'s sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MAKENA (AUTOINJECTOR):-

You can seek FDA approval to launch a generic drug before the expiration of MAVENCLAD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MAVENCLAD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MAVENCLAD:-

You can seek FDA approval to launch a generic drug before the expiration of REXULTI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REXULTI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REXULTI:-

You can seek FDA approval to launch a generic drug before the expiration of SAPHRIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SAPHRIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SAPHRIS:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of SPIRIVA RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SPIRIVA RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SPIRIVA RESPIMAT:-

You can seek FDA approval to launch a generic drug before the expiration of STIOLTO RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STIOLTO RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STIOLTO RESPIMAT:-

You can seek FDA approval to launch a generic drug before the expiration of STRIBILD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STRIBILD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STRIBILD:-

You can seek FDA approval to launch a generic drug before the expiration of SYMBICORT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SYMBICORT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SYMBICORT:-

You can seek FDA approval to launch a generic drug before the expiration of SYNRIBO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SYNRIBO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SYNRIBO:-

You can seek FDA approval to launch a generic drug before the expiration of UPTRAVI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the UPTRAVI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on UPTRAVI:-